Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 362,745
  • Shares Outstanding, K 45,859
  • Annual Sales, $ 8,350 K
  • Annual Income, $ -49,590 K
  • 60-Month Beta 1.03
  • Price/Sales 45.07
  • Price/Cash Flow N/A
  • Price/Book 2.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.50
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.19 +8.34%
on 11/18/19
9.56 -18.51%
on 11/25/19
-0.57 (-6.82%)
since 11/05/19
3-Month
7.19 +8.34%
on 11/18/19
10.34 -24.66%
on 09/27/19
-0.01 (-0.13%)
since 09/05/19
52-Week
6.30 +23.65%
on 08/05/19
13.66 -42.97%
on 04/11/19
-4.48 (-36.51%)
since 12/04/18

Most Recent Stories

More News
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

RCUS : 7.79 (-1.52%)
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.4300 (-0.23%)
BMY : 59.48 (+0.98%)
INFI : 1.25 (-1.57%)
RCUS : 7.79 (-1.52%)
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.4300 (-0.23%)
BMY : 59.48 (+0.98%)
INFI : 1.25 (-1.57%)
RCUS : 7.79 (-1.52%)
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space

Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma....

BMY : 59.48 (+0.98%)
RHHBY : 38.4300 (-0.23%)
INFI : 1.25 (-1.57%)
RCUS : 7.79 (-1.52%)
Infinity Initiates 2 Studies for Lead Candidate IPI-549

Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.

BMY : 59.48 (+0.98%)
RHHBY : 38.4300 (-0.23%)
INFI : 1.25 (-1.57%)
RCUS : 7.79 (-1.52%)
Arcus Biosciences to Present at Upcoming Investor Conferences

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the Company will participate in the following...

MS : 49.07 (+0.47%)
RCUS : 7.79 (-1.52%)
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -72.97% and -61.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

RCUS : 7.79 (-1.52%)
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q2 Earnings Expected to Decline

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RCUS : 7.79 (-1.52%)
Infinity (INFI) Earnings and Sales Miss Estimates in Q1

Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.

RHHBY : 38.4300 (-0.23%)
BMY : 59.48 (+0.98%)
INFI : 1.25 (-1.57%)
RCUS : 7.79 (-1.52%)
Trade Anxieties Return with a Vengeance

Trade Anxieties Return with a Vengeance

BIDU : 116.75 (+2.22%)
VRTX : 223.07 (-0.38%)
NBIX : 116.48 (-1.76%)
LYV : 70.13 (+0.94%)
RCUS : 7.79 (-1.52%)
UVXY : 15.91 (-2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RCUS with:

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

2nd Resistance Point 8.08
1st Resistance Point 7.94
Last Price 7.79
1st Support Level 7.69
2nd Support Level 7.58

See More

52-Week High 13.66
Fibonacci 61.8% 10.85
Fibonacci 50% 9.98
Fibonacci 38.2% 9.11
Last Price 7.79
52-Week Low 6.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar